Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results

Niraparib (NIRA) is a highly selective inhibitor of poly (adenosine diphosphate-ribose) polymerase, PARP1 and PARP2, which play a role in DNA repair. The phase II QUEST study evaluated NIRA combinations in patients with metastatic castration-resistant prostate cancer who were positive for homologous...

Descripción completa

Detalles Bibliográficos
Autores principales: Chi, Kim N, Fleshner, Neil, Chiuri, Vincenzo Emanuele, Van Bruwaene, Siska, Hafron, Jason, McNeel, Douglas G, De Porre, Peter, Maul, Raymond Scott, Daksh, Mahesh, Zhong, Xiaogang, Mason, Gary E, Tutrone, Ronald F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166146/
https://www.ncbi.nlm.nih.gov/pubmed/36994854
http://dx.doi.org/10.1093/oncolo/oyad008
Descripción
Sumario:Niraparib (NIRA) is a highly selective inhibitor of poly (adenosine diphosphate-ribose) polymerase, PARP1 and PARP2, which play a role in DNA repair. The phase II QUEST study evaluated NIRA combinations in patients with metastatic castration-resistant prostate cancer who were positive for homologous recombination repair gene alterations and had progressed on 1 prior line of novel androgen receptor-targeted therapy. Results from the combination of NIRA with abiraterone acetate plus prednisone, which disrupts androgen axis signaling through inhibition of CYP17, showed promising efficacy and a manageable safety profile in this patient population.

Ejemplares similares